Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify the source of chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, this spine-focused private practice is recognized for its expertise in complex procedures, early adoption of innovative technologies, and high surgical volume. The inclusion marks the first private practice site in the 300-patient randomized controlled study, reflecting growing interest in integrating Nociscan into real-world clinical workflows beyond academic medical centers.
“I have spent more than 25 years practicing spinal surgery in Beverly Hills, and my perspective is shaped not only by that experience, but also by having undergone multiple spine surgeries myself,” said Dr. Todd Lanman, neurosurgeon and founder of Lanman Spinal Neurosurgery. “We have made significant progress in moving beyond one-size-fits-all solutions for low back pain, driven by advances in technology and technique. Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
The CLARITY trial (Chronic Low bAck pain Randomized Independent Trial studY) is a prospective, multi-center study evaluating Nociscan in patients undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS scale at 12 months compared to baseline, with multiple secondary endpoints. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026. The addition of Lanman Spinal Neurosurgery accelerates enrollment and brings the study closer to generating high-quality evidence needed to advance Nociscan.
“Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice,” said Ryan Bond, Chief Strategy Officer of Aclarion. “Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY.”
Chronic low back pain affects approximately 266 million people worldwide. Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain using magnetic resonance spectroscopy. When used with other diagnostic tools, Nociscan provides critical insights into the location of pain and has demonstrated a 97% surgical success rate when all Nociscan-positive discs are treated. For more information about the CLARITY trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
